Quarterly report pursuant to Section 13 or 15(d)

Business Combinations (Details Textual)

v2.4.0.6
Business Combinations (Details Textual) (USD $)
In Millions, unless otherwise specified
1 Months Ended 7 Months Ended 9 Months Ended
Jan. 31, 2012
Dec. 31, 2011
Jan. 31, 2011
medications
company
licensee
Jul. 31, 2012
Sep. 30, 2012
employee
Jan. 24, 2011
Business Combinations (Textual) [Abstract]            
Number of FDA-approved medications     6      
Number of licensees     3      
Minimum number of companies supported by CyDex for drug development efforts     40      
Cash paid to CyDex shareholders           $ 31.6
Contingent Value Rights fair value           17.6
Discounted to present value using a discount rate           21.60%
Fair Value of Contingent liability         7.6  
Paid to CyDex shareholders 4.3 2.0   3.5 0.3  
Percentage of related revenue         20.00%  
Amount exceeds to get related revenue for CyDex share holders         15.0  
Percentage of related revenue additional         10.00%  
Aggregate CyDex-related revenue         35.0  
Payments to Acquire Businesses, Net of Cash Acquired 4.3 2.0   3.5 0.3  
Percentage of related revenue, current year         20.00%  
Amount excess of CyDex-related revenue         15  
Number of employees required         5  
Investments for acquiring employees         1.5  
Clinical and Regulatory Milestones [Member]
           
Business Combinations (Textual) [Abstract]            
Additional amount required to pay 4.0          
Milestones with Former License Holders [Member]
           
Business Combinations (Textual) [Abstract]            
Additional amount required to pay $ 4.0